Every material Form 8-K Incannex Healthcare Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
In a corporate update furnished under Item 7.01, Incannex said patient dosing has started in its DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, and that a U.S. composition and methods patent covering IHL-42X was granted with a baseline expiry in 2040. The company reported approximately $70 million in cash and no debt as of August 31, 2026. The filing contains no financial results or guidance, so the update covers clinical progress, intellectual property and capital position.
DReAMzz study runs at 13 clinical trial sites in the United States; dosing was first announced on August 25, 2026.
U.S. Patent and Trademark Office granted a patent on June 25, 2026, with a baseline expiry of July 9, 2040.
Cash of approximately $70 million and no debt as of August 31, 2026; more than A$11.2 million in non-dilutive tax incentive refunds received during 2026.
PSX-001 for generalized anxiety disorder has an open U.S. IND for a Phase 2b study (PsiGAD2) and a scientific advice meeting with the UK MHRA.
Incannex Healthcare announced on August 25, 2026 that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, its oral drug candidate for obstructive sleep apnea. The company says the study is designed to inform dose selection for its planned Phase 3 program. The filing contains no financial results, guidance or funding figures.
First patient dosed in the DReAMzz Phase 2 study, announced August 25, 2026
All 14 DReAMzz sites have Institutional Review Board approval, and the study uses 14 clinical trial sites across the United States
Builds on prior Phase 2 RePOSA results showing statistically significant AHI reductions versus placebo, with individual reductions of up to 83%, and FDA Fast Track designation for IHL-42X
Incannex Healthcare said it received a final A$5,102,788.30 refund under the Australian Government's Research and Development Tax Incentive Program, after the amended FY25 income tax return was approved. The company says this brings its 2026 non-dilutive receipts under this program to more than A$11.2 million, with no shareholder dilution. The filing reports no change to revenue, earnings, or guidance.
Final refund of A$5,102,788.30 received, announced August 11, 2026
Previously announced refund of A$6,039,162.43 brings 2026 total to more than A$11.2 million
Refund follows Australian government approval of overseas findings and amendment of the FY25 income tax return
Company expects additional R&D Tax Incentive funding in 2027 for eligible ongoing activities
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Incannex Healthcare Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →